insights_auto
Why is ABUS up 2.36%?
Dive Deeperchevron_right
ABUS:NASDAQ
Arbutus Biopharma Corp
$4.33
arrow_upward
+2.36%(+0.100) 1D
Oct 20, 1:48:27 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABUS...
Open
$4.24
High
$4.33
Low
$4.22
Mkt. cap
856.81M
Avg. vol.
6.69M
Volume
710.11K
P/E ratio
5.53
52-wk high
$5.45
52-wk low
$3.50
EPS
$0.78
Beta
0.76
Shares outstanding
198.11M
No. of employees
19
Open
$4.24
High
$4.33
Low
$4.22
Mkt. cap
856.81M
Avg. vol.
6.69M
Volume
710.11K
P/E ratio
5.53
52-wk high
$5.45
52-wk low
$3.50
EPS
$0.78
Beta
0.76
Shares outstanding
198.11M
No. of employees
19
News stories
From web sources and news partners
Stocktwits
·
23 minutes ago
Stock Market Correction In Its ‘Final Innings,’ Says Morgan Stanley’s Investment Chief
TradingView
·
56 minutes ago
Bitcoin volatility is now quieter than roughly 20% of the S&P 500
Yahoo Finance
·
31 minutes ago
Ciena (CIEN): Is the AI-Optical Boom Enough to Carry It Into the S&P 500?
Insider Monkey
·
20 minutes ago
Okta (OKTA): Does the AI-Identity Turnaround Make It a Stronger S&P 500 Contestant?
Profile
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
About Arbutus Biopharma Corp
CEOWilliam H. Collier
Employees19
Founded2007
HeadquartersWarminster Township, Pennsylvania, United States
SectorBiotechnology
Websitearbutusbio.com